SCHEMBL264929

SCHEMBL264929

CCC1SC(=O)NC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16924077 1.00
SCHEMBL11169825 0.82 TSHR (0.53)
SCHEMBL22623764 0.82 TSHR (0.53)
SCHEMBL11172424 0.80 TSHR (0.52)
SCHEMBL13323568 0.79
SCHEMBL13547513 0.77
SCHEMBL3072014 0.77
SCHEMBL20150476 0.77 TSHR (0.48)
SCHEMBL645409 0.77 EPHX2 (0.62)
SCHEMBL4859372 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016868-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2024-06-25 US disclosed
WO-2023205807-A2 PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2023-10-26 WO disclosed
US-20230303581-A1 ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS UNIV MISSISSIPPI (US) 2023-09-28 US disclosed
US-20230265055-A1 STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS OXFORD FINANCE LLC 2023-08-24 US disclosed
EP-3781564-B1 PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF CANCER SKYHAWK THERAPEUTICS INC (US) 2023-08-23 EP disclosed
WO-2023150534-A1 SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-08-10 WO disclosed
US-20230219893-A1 Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease US GOV VETERANS AFFAIRS (US) 2023-07-13 US disclosed
WO-2023108098-A1 A NEW ROUTE FOR SYNTHESIZING AXIALLY CHIRAL CANNABINOIDS FROM COUMARINS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-06-15 WO disclosed
US-11643394-B2 Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-05-09 US disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 US disclosed
US-20070122444-A1 Medical devices employing triazine compounds and compositions thereof DR. REDDY'S LABORATORIES LTD. (IN) 2007-05-31 US disclosed
US-20070117795-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2007-05-24 US disclosed
US-20070099874-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-05-03 US disclosed
US-20070099874-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-05-03 US disclosed
US-20070099976-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-05-03 US disclosed
US-20070072904-A1 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders PLEXXIKON INC 2007-03-29 US disclosed
US-20070066662-A1 PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES SMITHKLINE BEECHAM PLC 2007-03-22 US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 US disclosed
WO-2004052869-A1 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-06-24 WO disclosed